Little is known about whether there is a relationshipbetweenPI3K/AKT, ERK1/2 and an inverted CCAAT box binding protein (ICBP90) in biological behaviours of tumour cells. The aim of this study was to determine thisusing Jurkat T cells. Compared to PD98059 (an ERK1/2 signaling inhibitor), DAPT (a Notch signaling inhibitor) or adriamycin (a classical anti-tumour drug), the inhibition of Jurkat T cell growth by LY294002 (a PI3K/Akt signaling inhibitor) was more obvious. LY294002 combined with adriamycin appeared to have a synergistic effect. LY294002 strongly blocked Jurkat T cells at each phase of cell cycle with a decrease of DNA content, superior to adriamycin. Consistent with these changes, the expression of phosphorylated ERK1/2 was markedly decreased in the LY294002-treated Jurkat T cells, leading to the reduction of ICBP90 production, followed by moderate attenuation of TGF-β secretion. The results suggest that deactivation of PI3K/Akt signalling can surpress Jurkat T cell growth through inhibiting cell proliferation and blocking the cell cycle. ICBP90 may mediate the PI3K/AKT-ERK1/2 signalling to regulate leukemia cell growth.
Introduction
A phosphatidylinositol 3-kinase (PI3K) pathway regulates various cellular processes, such as proliferation, growth, apoptosis and cytoskeletal rearrangement. PI3K catalytic activity is tightly regulated in normal cells by various mechanisms. A primary consequence of PI3K activation is the expression of PIP3 on the cell membrane, which functions as a secondary messenger to activate downstream pathways that involve Akt (a cellular homologue of the retroviral oncogene v-Akt) and other proteins [1] . Akt is found in various intracellular locations and has a variety of different functions in the regulation of cellular processes [2, 3] . Akt on the cell membrane is phosphorylated at Thr308 and Ser473 by Pdk1 and the mammalian target of rapamycin (mTOR) complex (mTORC)-2, respectively [4] . Activated Akt moves to the cytoplasm and nucleus, where it phosphorylates and activates target proteins involved in different cellular functions [5] . Akt acts downstream of PI3K to regulate many biological processes such as proliferation, apoptosis and growth.Other signalling pathways are also known to be regulated by PI3K activity and might be involved in PI3K-mediated tumorigenesis [1] .
LY294002, a PI3K inhibitor, has been widely used to study the function of PI3K in cellular responses [7] . It acts at an ATP-binding site of PI3K enzyme, thus selectively inhibiting the PI3K-Akt nexus. LY294002 is shown to exert anti-tumorigenic effect in vivo and in vitro by the induction of apoptosis and cell growth arrest [8, 9] . Moreover, tumour cell invasion and migration could be significantly attenuated by LY294002 treatment in several tumour models [10, 11] . Until now, most studies on LY294002 attribute its anti-cancer activity to the inhibition of the PI3K pathway [6] .
ICBP90 (an inverted CCAAT box binding protein of 90 kD) was identified as a nuclear protein that binds to one of the inverted CCAAT boxes of the topoisomerase IIα (TopoIIα) gene promoter. It acts as a transcriptional factor and regulates expression of the TopoIIa gene during the cell cycle. In a recent report, it has been demonstrated that overexpression of ICBP90 in normal cells is associated with an elevation of TopoIIa expression and an increase in cell proliferation rate. ICBP90 also has a function in cell-cycle regulation:expression of ICBP90 is observed throughout the cell cycle but peaks at late-phase G 1 and G 2 /M phases in noncancerous human cells [12] . ICBP90 inhibitors could inhibit the expression of ICBP90, arresting the cell cycle at the G 1 /G 0 stage and blocking its entrance from S phase to G 2 /M phase. ICBP90 exhibits anti-apoptosis properties and Jurkat T cell apoptosis depends upon ICBP90 expression down-regulation [13] . Christian Bronner found that CK2 (casein kinase2) may be an important regulator of the transcriptional activity of ICBP90 and "ICBP90 family" members may be substrates for CK2 [14] . Taken together, the above mentioned reports have shown that PI3K/AKT, extracellular signal-regulated kinase 1/2 (ERK1/2) and ICBP90 all have the ability to greatly affect normal or tumour cell biological behaviours. Therefore, we hypothesized that there might be relationships between them in controlling the biological behaviours of tumour cells. In the current study, we tried to ascertain whether there is a relationship between ICBP90and thecontrol of tumour cell growth by PI3K/AKT and ERK1/2 signals.
Experimental Procedures

Cell culture and treatment
Jurkat T cells, a human T cell lymphoma cell line (China Center for Type Culture Collection Wu Han University), were used to study the effects of different concentrations of LY294002 on cell colony formation and proliferation, apoptosis and ICBP90 expression. 
Cell viability
Jurkat T cells were seeded into 96-well plates at a density of 1x10 5 cells/well in a RPMI-1640 medium supplemented with 10% heat inactivated fetal bovine serum. The cells were treated with adriamycin as a positive control. The above treated cells were first observed under an inverted microscope 24 h after the treatment, then 10 μl of 5 ng mL -1 MTT was added into the cells per well. After 4 h incubation at 37°C, the cells were centrifuged at 250 g for 5 min to precipitate formazan crystals and the supernatant was removed. To dissolve the formazan crystals, 100 μl of dimethylsulfoxide was added and then the mixture was incubated for 10 min at room temperature in darkness. The optical density (OD) of the formazan solution was measured at 490 nm on a 680 type microplate reader (Bio-Rad, Berkeley, CA, USA).
Cell cycle
Jurkat T cells were seeded in 96 well microplates at a concentration of 4×10 5 cells/well, and cultured with adriamycin, PD98059, LY294002, adriamycin plus LY294002 and adriamycin plus PD98059 at 37°C in the presence of 5% CO 2 for 48 h. The cells were collected and re-suspended in 300 μl of PBS containing 100 μl fetal calf serum (FCS) and then 700 μl ethanol was added. After being kept on ice for 30 min, the samples were washed twice with PBS, followed by incubation with 400 μl propidium iodide (PI) solution (50 μg mL -1 PI, 1 μl mL -1 TritonX-100, 0.1 mM L -1 EDTA and 50 μl mL -1 RNase) (KeyGen, Nanjing, China) for 15 min at room temperature in darkness. DNA content was determined by a flow cytometer using CellQuest software (FACSCalibur, Becton Dickinson, USA).
Flow cytometry
1×10
5 Jurkat T cells per well were seeded in 6-well plates in RPMI-1640 medium supplemented with 10% FCS. The cells were then incubated with either vehicle or different concentrations of LY294002 (1, 3.75, 7.5,15 and 30 μM L -1 ) or 500 ng mL -1 adriamycin for 48 h. Afterwards, all the cells were washed with ice-cold PBS and adjusted to a concentration of 2×10 5 cells mL -1 . They were then stained with annexin V-FITC and PI in binding buffer (10 mM L -1 HEPES, 140 mM L -1 NaCl, and 2.5 mM L -1 CaCl 2 ). Finally, 10,000 cells for each sample were analyzed under a flow cytometer using CellQuest software.
Western blot
As described above, the cells were treated for 0.5 -24 h or 24 h. They were then collected and lysed in 100 μl RIPA lyse solution supplemented with 1μl PMSF (Biocolors, Shanghai, China), and kept on ice for 1 h. The lysates were clarified by centrifugation at 4°C for 20 min at 12,000 rpm. The denatured samples were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresisand transferred to nitrocellulose membranes (Amersham Biosciences, Pittsburgh, PA, USA). The membranes were blocked with TBS containing 0.05% Tween 20 (TBST) and 5% non-fat milk at room temperature for 1 h. After being washed, the membranes were probed with anti-ERK1/2 antibody (1:1000), anti-P-ERK1/2 antibody (1:1000)(Cell Signaling, Danvers, MA, USA), anti-ICBP90 antibody (1:4000) (gifted from Dr. Christian Bronner, Institut National de la Sante et de la Recherche Medicale/Universite Louis Pasteur, France) and anti-β-actin primary antibody (1:500) at room temperature for 2 h. The membranes were then labelled with HRP-conjugated anti-IgG antibodies for 1 h at room temperature. The bands were visualized by ECL (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer's instructions. The band density was checked by the FluorChem 8000 image system (Alpha Innotech, Santa Clara, CA, USA).
ELISA
Jurkat T cells at a density of 5×10 5 cells mL -1 were seeded into a 12-well plate and treated with adriamycin, LY294002, PD98059, adriamycin plus PD98059, or adriamycin plus LY294002 at 37°C for 24 h. The cultured supernatant was then collected. The concentration of transforming growth factor-beta (TGF-β) was assessed usingan enzyme linked immunosorbent assay (ELISA) with a humanTGF-β ELISA Kit (Dakewe Biotech Company Limited, Shenzhen, China) according to the 
Statistical analysis
SPSS 10.0 software (SPSS Inc., IL, US) was used for statistical analysis. The results were expressed as means ± SD of three independent experiments. Individual comparisons were made by Student's t-test for paired data and P-values less than 0.05 were considered to be significant.
Results
LY294002 inhibits Jurkat T cell growth
The cells were treated with different drugs (1000 ng mL . They were all found to promote inhibition of cell growth, but LY294002 or LY294002 plus adriamycin resulted in more distinct changes in cell density. Compared to other groups, the colony formation of LY294002-treated cells was reduced. Although adriamycin also inhibited the growth of Jurkat T cells, it did not lead to distinct changes in the size of colonies formed. PD98059 plus adriamycin resulted in the reduction of viable cells and colony size, but their effect was less than that ofLY294002 plus adriamycin (Figure 1) . The colony size and the number of the cells were significantly decreased with increasing concentrations of LY294002 (Figure 2) . Our results indicate that LY294002 obviously inhibits the colony formation of Jurkat T cells and the combination of LY294002 with adriamycin has a synergistic action.
Consistent with the above results, the MTT assay further supported the conclusion that LY294002 could suppress Jurkat T cell proliferation in a dose-related or time-related manner. As shown in Figure 3 , the cells were significantly inhibited by LY294002 or LY294002 plus adriamycin. The combination of LY294002 with adriamycin exhibited a greater effect of the used drugs. The inhibitory rate of Jurkat T cells was most significant at 24, and 48 h after the treatment with LY294002.
LY294002 blocks Jurkat T cell cycle at each phase
DNA content from Jurkat T cells treated with different drugs was determined by flow cytometry. Compared with the control, adriamycin was found to arrest the cells at G 2 /M phase and increase the apoptotic proportion of Sub-G 0 /G 1 phase. Dissimilar to adriamycin, LY294002 strongly blocked the cells at each phase, and the combination of LY294002 with adriamycin presented a great effect (Figure 4 ).
LY294002 enhances the early-phase apoptotic rate of Jurkat T cells
Following treatment with different concentrations of LY294002, Jurkat T cells were stained with Annexin V/PI and subjected to flow cytometry analysis. As shown in Figure 5 , the early-phase apoptotic rates of the cells )for 24 h, respectively. Then, they was examined under an inverted microscope (magnification: ×200). were increased with the increasing concentrations of LY294002, compared to the control. The highest apoptotic rate was in the 30 μM L -1 LY294002 group (11.2%). Nevertheless, the rate in the 500 ng mL 
LY294002 decreases the expressions of P-ERK1/2 and ICBP90 in Jurkat T cells
Jurkat T cells were treated with LY294002 at the indicated time. The expression of P-ERK1/2 were decreased with extension of exposure time within 6 h after the treatment, appearing more obvious at 0.5 and 3 h. But there was no significant difference in the expression of ERK1/2 ( Figure 6A ).
In order to observe the effect of LY294002 on expression of ICBP90, levels of ICBP90 were detected by Western blot. ICBP90 expression decreased with the increasing doses of LY294002 from 1 to 30 μM L -1 , appearing more obvious at the dose of 30 μM L -1 . ICBP90 started to decrease 2 h after the treatment with LY294002. PD98059, DAPT and the high dose of adriamycin all down-regulated ICBP90 expression to differing extents. However, the downregulation of ICBP90 by LY294002 was most distinct. LY294002 plus adriamycin inhibited the expression of ICBP90 more than LY294002 or adriamycin used alone. The data suggest that LY294002 can strongly block ICBP90 expression, which may be correlated with the inhibition of ERK1/2 signalling pathway activation ( Figure 6B-D) . 
Moderate attenuation of TGF-β secretion in Jurkat T cellsis caused by LY294002
As shown in Table 1 , production of TGF-βwas decreased following treatment of Jurkat T cells with different inhibitors. Adriamycin inhibited TGF-β production more distinctly than other drugs. LY294002 or LY294002 plus adriamycin were also found to inhibit the level of TGF-β, but with no significant difference between them. The result suggests that the inhibition of Jurkat T cells by LY294002 may also be related to the decrease inTGF-β (Table 1 ). 
Discussion
The PI3K pathway regulates various cellular behaviours such as proliferation, growth, apoptosis and cytoskeletal rearrangement. Akt acts downstream of PI3K to regulate many biological processes such as proliferation, apoptosis and growth. However, other signalling pathways are also known to be regulated by PI3K activity and might be involved in PI3K-mediated tumorigenesis [1] . Deregulated activation of this pathway, as a result of numerous genetic and epigenetic alterations, has been found in many types of cancer including leukaemias, breast cancer, AML and so on [6] . LY294002 is a commonly used pharmacologic inhibitor of PI3K. It acts at the ATP-binding site of the PI3K enzyme, thus selectively inhibiting the PI3K-Akt nexus [12] . Therefore, in the current study we used adriamycin as a positive control to observe the effects of deactivation of PI3K signalling on human T cell lymphoma cell growth, and to investigate the relationships between PI3K and ERK1/2 signals with ICBP90. Based on colony formation of Jurkat T cells, we found that LY294002 reduced the number and size of the cell clusters. LY294002 was able to strongly block the cell cycle at each phase and induce moderate apoptosis at an early-phase. These results support the idea that blockingPI3K signalling activation can inhibit malignant growth oflymphoma cells. It is well-known that the ERK1/2 signalling pathway is also related to tumour cell growth. In another aspect, ICBP90 was found to be a key protein for the G1/S phase checkpoint. Whether is there any relationship between them is the next question. Tumorigenesis is mainly due to checkpoint errors at G 1 /S and G 2 /M phases, allowing cells to become cancerous and proliferate malignantly. Treatment with a selective inhibitor such as LY294002 acting on the PI3k signalling pathway can cause some cells to arrest at G 1 phase [15, 16] , for example C81, MT-2, HUT102, but other cells arrest at G 2 /M phase, for example HEK293 [17, 18] . Interestingly, our data showed that LY294002 could strongly block the cell cycle at each phase rather than just causing arrest at a specific phase, unlike the negative or positive controls It is known that cyclins play an important role in cellcycle regulation. Some cyclins only affect G 1 /S transition, while other cyclins play a role in M phase or G 2 /M phase. Each phase of the cell cycle is also governed by different cyclin-dependent kinases (CDKs),which is related to many inhibitory proteins of CDKs. Therefore, we speculate that influence of thePI3k signalling pathway on tumour cell cycle might not just be limited to the role of the PI3k signalling pathway itself.
ICBP90 is highly expressed at G 1 and G 2 phases in normal cells and plays a role in the G 1 /S and G 2 /M transition.
P53/P21cip/WAF1 down-regulate the expression of ICBP90 and cause the cell to arrest at the last phase [19] . High expression of ICBP90 causes cells to skip the cell cycle checkpoint and therefore the expression level of ICBP90 in tumour cells is much higher than in normal cells.The current data showed that LY294002 inhibited proliferation and blocked the cell cycle of leukemia cells effectively. The question to ask is then whether this role is associated with alteration of ICBP90 expression? We found that the expression of ICBP90 was decreased with increasing doses of LY294002 from 1 to 30 μM L -1
. Phosphorylated ERK1/2 was also attenuated by blocking PI3K signalling before the reduction of ICBP90. These changes were consistent with those of the cell proliferation and cell cycle caused by the block of PI3K signalling. Thus, all the results suggest that there may be a connection between the three molecules. It was reported that LY294002 could activate P53 and P21 signalling. In addition, the activated P53 and P21 down-regulated the expression of ICBP90, which would affect the cell cycle of JurkatT cells. Hence, a detailed mechanistic process remains to be investigated.
Additionally, TGF-β is a pleiotropic polypeptide growth factor that mediates transformation of non-neoplastic rat kidney and murine AKR-2B fibroblasts [20, 21] , while it induces growth arrest and apoptosis in epithelial cells. It is revealed that TGF-β acts as a tumour suppressor in premalignant epithelial cells, whereas it exerts pro-oncogenic effects in metastatic tumours [22, 23] . TGF-β is over expressed in many tumour cells, including prostate cancer, and tumour cells reduce the expression of the TGF-β receptor to avoid the growth inhibition signal [24] . Many cells escape growth inhibition, leading to uncontrolled cell proliferation and tumorigenesis. Our data showed that the level of TGF-β in Jurkat T cells was reduced by treatment with the different inhibitors but that the down-regulation of TGF-β by adriamycin was more significant. This result indicates that inhibition of LY294002 on the proliferation of Jurkat T cells is also related to the reduction of TGF-β production.
In summary, there has, to date, been no study on the connection between ICBP90, PI3K/Akt and ERK1/2 signalling pathways on the regulation of leukaemia cell growth. All of our data demonstrate that blocking PI3K/Akt signalling can strongly inhibit Jurkat T cell growth. ICBP90 may mediate the PI3K/Akt-ERK1/2 signalling pathway to control leukaemia cell growth. Junction points of ICBP90 with PI3K/Akt and ERK1/2 signalling pathways merit further to be explored.
